Meeting
2015 ASCO Annual Meeting
Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
Authors
Christian K. Kollmannsberger
BC Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada
Christian K. Kollmannsberger , Sunil Sharma , Geoffrey Shapiro , Kim N. Chi , James Christensen , Vanessa Roberts Tassell , Richard C. Chao , Demiana Faltaos , Herbert Hurwitz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Signal Transduction
Clinical Trial Registration Number
NCT00697632
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2589)
DOI
10.1200/jco.2015.33.15_suppl.2589
Abstract #
2589
Poster Bd #
305
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.
First Author: Todd Michael Bauer
Poster
2019 ASCO Annual Meeting
Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.
First Author: Dana Backlund Cardin
Poster
2018 ASCO Annual Meeting
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).
First Author: Andrew J. Wagner
Poster
2018 ASCO Annual Meeting
A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.
First Author: Ruihua Xu